Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients

Science Signaling

Volumn 8, Issue 408, 2015, Pages

  Fey, Dirk ^a   Halasz, Melinda ^a   Dreidax, Daniel ^b   Kennedy, Sean P ^a   Hastings, Jordan F ^c   Rauch, Nora ^a   Munoz, Amaya Garcia ^a   Pilkington, Ruth ^a   Fischer, Matthias ^d,e,f   Westermann, Frank ^b   Kolch, Walter ^a   Kholodenko, Boris N ^a   Croucher, David R ^a,c,g  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; STRESS ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TUMOR MARKER; ZEBRAFISH PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CELL STRESS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MYCN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; OVERALL SURVIVAL; POSITIVE FEEDBACK; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; ZEBRA FISH; ADOLESCENT; ANIMAL; BIOLOGICAL MODEL; CHILD; DISEASE FREE SURVIVAL; EXPERIMENTAL NEOPLASM; FEMALE; FOLLOW UP; INFANT; MALE; METABOLISM; MORTALITY; PREDICTIVE VALUE; PRESCHOOL CHILD; SURVIVAL RATE; TUMOR CELL LINE;

ADOLESCENT; ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; MAP KINASE KINASE 4; MODELS, BIOLOGICAL; NEOPLASMS, EXPERIMENTAL; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; SIGNAL TRANSDUCTION; SURVIVAL RATE; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84954479859     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aab0990     Document Type: Article

References (71)

1. R. J. Davis, Signal transduction by the JNKgroup ofMAPkinases.Cell 103, 239-252 (2000).
2. C. Bakal, R. Linding, F. Llense, E. Heffern, E. Martin-Blanco, T. Pawson, N. Perrimon, Phosphorylation networks regulating JNK activity in diverse genetic backgrounds. Science 322, 453-456 (2008).
3. J. Cheng, Y.-H. Fan, X. Xu, H. Zhang, J. Dou, Y. Tang, X. Zhong, Y. Rojas, Y. Yu, Y. Zhao, S. A. Vasudevan, H. Zhang, J. G. Nuchtern, E. S. Kim, X. Chen, F. Lu, J. Yang, A smallmolecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 5, e1079 (2014).
4. L. Li, Z. Feng, A. G. Porter, JNK-dependent phosphorylation of c-Jun on serine 63 mediates nitric oxide-induced apoptosis of neuroblastoma cells. J. Biol. Chem. 279, 4058-4065 (2004).
5. Y.-J. Liu, Z.-Z. Guan, Q. Gao, J.-J. Pei, Increased level of apoptosis in rat brains and SH-SY5Y cells exposed to excessive fluoride-a mechanism connected with activating JNK phosphorylation. Toxicol. Lett. 204, 183-189 (2011).
6. K. Newhouse, S.-L. Hsuan, S. H. Chang, B. Cai, Y. Wang, Z. Xia, Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol. Sci. 79, 137-146 (2004).
7. S. Osone, H. Hosoi, Y. Kuwahara, Y. Matsumoto, T. Iehara, T. Sugimoto, Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen speciesdependent manner in neuroblastoma cells. Int. J. Cancer 112, 219-224 (2004).
8. G. Pagnan, D. Di Paolo, R. Carosio, F. Pastorino, D. Marimpietri, C. Brignole, A. Pezzolo, M. Loi, L. J. V. Galietta, F. Piccardi, M. Cilli, B. Nico, D. Ribatti, V. Pistoia, M. Ponzoni, The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin. Cancer Res. 15, 1199-1209 (2009).
9. R. K. Singh, L. Dorf, A. DeMartino, S. Illenye, K. Koto, E. A. Currier, T. Ashikaga, K. K. Kim, L. Brard, G. L. S. Sholler, Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro. Cancer Biol. Ther. 11, 1036-1045 (2011).
10. V. Waetzig, U. Wacker, W. Haeusgen, B. Björkblom, M. J. Courtney, E. T. Coffey, T. Herdegen, Concurrent protective and destructive signaling of JNK2 in neuroblastoma cells. Cell. Signal. 21, 873-880 (2009).
11. E. F. Wagner, Á. R. Nebreda, Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537-549 (2009).
12. M. Fosbrink, N.-N. Aye-Han, R. Cheong, A. Levchenko, J. Zhang, Visualization of JNK activity dynamics with a genetically encoded fluorescent biosensor. Proc. Natl. Acad. Sci. U.S.A. 107, 5459-5464 (2010).
13. J.-J. Ventura, A. Hübner, C. Zhang, R. A. Flavell, K. M. Shokat, R. J. Davis, Chemical genetic analysis of the time course of signal transduction by JNK. Mol. Cell 21, 701-710 (2006).
14. C. P. Bagowski, J. Besser, C. R. Frey, J. E. Ferrell Jr., The JNK cascade as a biochemical switch in mammalian cells: Ultrasensitive and all-or-none responses. Curr. Biol. 13, 315-320 (2003).
15. C. P. Bagowski, J. E. Ferrell Jr., Bistability in the JNK cascade. Curr. Biol. 11, 1176-1182 (2001).
16. D. Fey, D. R. Croucher, W. Kolch, B. N. Kholodenko, Crosstalk and signaling switches in mitogen-activated protein kinase cascades. Front Physiol. 3, 355 (2012).
17. G. M. Brodeur, J. Pritchard, F. Berthold, N. L. Carlsen, V. Castel, R. P. Castelberry, B. De Bernardi, A. E. Evans, M. Favrot, F. Hedborg, Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11, 1466-1477 (1993).
18. J. M. Maris, M. D. Hogarty, R. Bagatell, S. L. Cohn, Neuroblastoma. Lancet 369, 2106-2120 (2007).
19. I. ∅ra, A. Eggert, Progress in treatment and risk stratification of neuroblastoma: Impact on future clinical and basic research. Semin. Cancer Biol. 21, 217-228 (2011).
20. X. X. Tang, H. Zhao, B. Kung, D. Y. Kim, S. L. Hicks, S. L. Cohn, N.-K. Cheung, R. C. Seeger, A. E. Evans, N. Ikegaki, The MYCN enigma: Significance of MYCN expression in neuroblastoma. Cancer Res. 66, 2826-2833 (2006).
21. J. M. Maris, K. K. Matthay, Molecular biology of neuroblastoma. J. Clin. Oncol. 17, 2264-2279 (1999).
22. S. Asgharzadeh, R. Pique-Regi, R. Sposto, H. Wang, Y. Yang, H. Shimada, K. Matthay, J. Buckley, A. Ortega, R. C. Seeger, Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J. Natl. Cancer Inst. 98, 1193-1203 (2006).
23. S. Zhu, J.-S. Lee, F. Guo, J. Shin, A. R. Perez-Atayde, J. L. Kutok, S. J. Rodig, D. S. Neuberg, D. Helman, H. Feng, R. A. Stewart, W. Wang, R. E. George, J. P. Kanki, A. T. Look, Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 21, 362-373 (2012).
24. D. M. Jandhyala, A. Ahluwalia, T. Obrig, C. M. Thorpe, ZAK: A MAP3Kinase that transduces Shiga toxin-and ricin-induced proinflammatory cytokine expression. Cell. Microbiol. 10, 1468-1477 (2008).
25. X. Wang, M. M. Mader, J. E. Toth, X. Yu, N. Jin, R. M. Campbell, J. K. Smallwood, M. E. Christe, A. Chatterjee, T. Goodson Jr., C. J. Vlahos, W. F. Matter, L. J. Bloem, Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J. Biol. Chem. 280, 19298-19305 (2005).
26. W. Engström, A. Ward, K. Moorwood, The role of scaffold proteins in JNK signalling. Cell Prolif. 43, 56-66 (2010).
27. E. A. Gross, M. G. Callow, L. Waldbaum, S. Thomas, R. Ruggieri, MRK, a mixed lineage kinase-related molecule that plays a role in g-radiation-induced cell cycle arrest. J. Biol. Chem. 277, 13873-13882 (2002).
28. C.-Y. Huang, W.-W. Kuo, P. J. Chueh, C.-T. Tseng, M.-Y. Chou, J.-J. Yang, Transforming growth factor-b induces the expression of ANF and hypertrophic growth in cultured cardiomyoblast cells through ZAK. Biochem. Biophys. Res. Commun. 324, 424-431 (2004).
29. L. Bardwell, Mechanisms of MAPK signalling specificity. Biochem. Soc. Trans. 34, 837-841 (2006).
30. H.-S. Park, M.-S. Kim, S.-H. Huh, J. Park, J. Chung, S. S. Kang, E.-J. Choi, Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J. Biol. Chem. 277, 2573-2578 (2002).
31. H. Zhang, X. Zha, Y. Tan, P. V. Hornbeck, A. J. Mastrangelo, D. R. Alessi, R. D. Polakiewicz, M. J. Comb, Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs. J. Biol. Chem. 277, 39379-39387 (2002).
32. N. M. Borisov, N. I. Markevich, J. B. Hoek, B. N. Kholodenko, Signaling through receptors and scaffolds: Independent interactions reduce combinatorial complexity. Biophys. J. 89, 951-966 (2005).
33. W. S. Hlavacek, J. R. Faeder, M. L. Blinov, A. S. Perelson, B. Goldstein, The complexity of complexes in signal transduction. Biotechnol. Bioeng. 84, 783-794 (2003).
34. M. L. Blinov, J. R. Faeder, B. Goldstein, W. S. Hlavacek, BioNetGen: Software for rule-based modeling of signal transduction based on the interactions of molecular domains. Bioinformatics 20, 3289-3291 (2004).
35. H. Conzelmann, D. Fey, E. D. Gilles, Exact model reduction of combinatorial reaction networks. BMC Syst. Biol. 2, 78 (2008).
36. M. S. Creamer, E. C. Stites, M. Aziz, J. A. Cahill, C. W. Tan, M. E. Berens, H. Han, K. J. Bussey, D. D. Von Hoff, W. S. Hlavacek, R. G. Posner, Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling. BMC Syst. Biol. 6, 107 (2012).
37. V. Danos, J. Feret, W. Fontana, R. Harmer, J. Krivine, Rule-based modelling of cellular signalling. CONCUR 2007-Concurrency Theory 4703, 17-41 (2007).
38. L. Ingber, Very fast simulated re-annealing. Math. Comput. Model 12, 967-973 (1989).
39. S. Hengl, C. Kreutz, J. Timmer, T. Maiwald, Data-based identifiability analysis of nonlinear dynamical models. Bioinformatics 23, 2612-2618 (2007).
40. T. Maiwald, J. Timmer, Dynamical modeling and multi-experiment fitting with PottersWheel. Bioinformatics 24, 2037-2043 (2008).
41. B. Schwanhäusser, D. Busse, N. Li, G. Dittmar, J. Schuchhardt, J.Wolf,W. Chen, M. Selbach, Global quantification of mammalian gene expression control. Nature 473, 337-342 (2011).
42. M. Mazumdar, J. R. Glassman, Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat. Med. 19, 113-132 (2000).
43. G. P. Tonini, A. Nakagawara, F. Berthold, Towards a turning point of neuroblastoma therapy. Cancer Lett. 326, 128-134 (2012).
44. D. C. Koboldt, R. S. Fulton, M. D. McLellan, H. Schmidt, J. Kalicki-Veizer, J. F. McMichael, L. L. Fulton, D. J. Dooling, L. Ding, E. R. Mardis, R. K. Wilson, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
45. A. V. Biankin, N.Waddell, K. S. Kassahn, M.-C. Gingras, L. B. Muthuswamy, A. L. Johns, D. K. Miller, P. J. Wilson, A.-M. Patch, J. Wu, D. K. Chang, M. J. Cowley, B. B. Gardiner, S. Song, I. Harliwong, S. Idrisoglu, C. Nourse, E. Nourbakhsh, S. Manning, S. Wani, M. Gongora, M. Pajic, C. J. Scarlett, A. J. Gill, A. V. Pinho, I. Rooman, M. Anderson, O. Holmes, C. Leonard, D. Taylor, S.Wood, Q. Xu, K. Nones, J. L. Fink, A. Christ, T. Bruxner, N. Cloonan, G. Kolle, F. Newell, M. Pinese, R. S. Mead, J. L. Humphris, W. Kaplan, M. D. Jones, E. K. Colvin, A. M. Nagrial, E. S. Humphrey, A. Chou, V. T. Chin, L. A. Chantrill, A. Mawson, J. S. Samra, J. G. Kench, J. A. Lovell, R. J. Daly, N. D. Merrett, C. Toon, K. Epari, N. Q. Nguyen, A. Barbour, N. Zeps; Australian Pancreatic Cancer Genome Initiative, N. Kakkar, F. Zhao, Y. Q. Wu, M. Wang, D. M. Muzny, W. E. Fisher, F. C. Brunicardi, S. E. Hodges, J. G. Reid, J. Drummond, K. Chang, Y. Han, L. R. Lewis, H. Dinh, C. J. Buhay, T. Beck, L. Timms, M. Sam, K. Begley, A. Brown, D. Pai, A. Panchal, N. Buchner, R. De Borja, R. E. Denroche, C. K. Yung, S. Serra, N. Onetto, D. Mukhopadhyay, M.-S. Tsao, P. A. Shaw, G. M. Petersen, S. Gallinger, R. H. Hruban, A. Maitra, C. A. Iacobuzio-Donahue, R. D. Schulick, C. L. Wolfgang, R. A. Morgan, R. T. Lawlor, P. Capelli, V. Corbo, M. Scardoni, G. Tortora, M. A. Tempero, K. M. Mann, N. A. Jenkins, P. A. Perez-Mancera, D. J. Adams, D. A. Largaespada, L. F. A. Wessels, A. G. Rust, L. D. Stein, D. A. Tuveson, N. G. Copeland, E. A. Musgrove, A. Scarpa, J. R. Eshleman, T. J. Hudson, R. L. Sutherland, D. A. Wheeler, J. V. Pearson, J. D. McPherson, R. A. Gibbs, S. M. Grimmond, Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
46. C. Curtis, S. P. Shah, S.-F. Chin, G. Turashvili, O. M. Rueda, M. J. Dunning, D. Speed, A. G. Lynch, S. Samarajiwa, Y. Yuan, S. Gräf, G. Ha, G. Haffari, A. Bashashati, R. Russell, S. McKinney; METABRIC Group, A. Langerød, A. Green, E. Provenzano, G. Wishart, S. Pinder, P.Watson, F. Markowetz, L. Murphy, I. Ellis, A. Purushotham, A.-L. Børresen-Dale, J. D. Brenton, S. Tavaré, C. Caldas, S. Aparicio, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
47. T.-C. Liu, C.-J. Huang, Y.-C. Chu, C.-C. Wei, C.-C. Chou, M.-Y. Chou, C.-K. Chou, J.-J. Yang, Cloning and expression of ZAK, a mixed lineage kinase-like protein containing a leucine-zipper and a sterile-alpha motif. Biochem. Biophys. Res. Commun. 274, 811-816 (2000).
48. H. Vin, S. S. Ojeda, G. Ching, M. L. Leung, V. Chitsazzadeh, D.W. Dwyer, C. H. Adelmann, M. Restrepo, K. N. Richards, L. R. Stewart, L. Du, S. B. Ferguson, D. Chakravarti, K. Ehrenreiter, M. Baccarini, R. Ruggieri, J. L. Curry, K. B. Kim, A. M. Ciurea, M. Duvic, V. G. Prieto, S. E. Ullrich, K. N. Dalby, E. R. Flores, K. Y. Tsai, BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife 2, e00969 (2013).
49. H. Vin, G. Ching, S. S. Ojeda, C. H. Adelmann, V. Chitsazzadeh, D. W. Dwyer, H. Ma, K. Ehrenreiter, M. Baccarini, R. Ruggieri, J. L. Curry, A. M. Ciurea, M. Duvic, N. L. Busaidy, N. M. Tannir, K. Y. Tsai, Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol. Cancer Ther. 13, 221-229 (2014).
50. R. Fritsche-Guenther, F. Witzel, A. Sieber, R. Herr, N. Schmidt, S. Braun, T. Brummer, C. Sers, N. Blüthgen, Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol. Syst. Biol. 7, 489 (2011).
51. O. E. Sturm, R. Orton, J. Grindlay, M. Birtwistle, V. Vyshemirsky, D. Gilbert, M. Calder, A. Pitt, B. Kholodenko, W. Kolch, The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci. Signal. 3, ra90 (2010).
52. B. Kholodenko, M. B. Yaffe, W. Kolch, Computational approaches for analyzing information flow in biological networks. Sci. Signal. 5, re1 (2012).
53. B. N. Kholodenko, Cell-signalling dynamics in time and space. Nat. Rev. Mol. Cell Biol. 7, 165-176 (2006).
54. B. N. Kholodenko, J. F. Hancock,W. Kolch, Signalling ballet in space and time. Nat. Rev. Mol. Cell Biol. 11, 414-426 (2010).
55. A. Oberthuer, D. Juraeva, B. Hero, R. Volland, C. Sterz, R. Schmidt, A. Faldum, Y. Kahlert, A. Engesser, S. Asgharzadeh, R. Seeger,M. Ohira, A. Nakagawara, P. Scaruffi, G. P. Tonini, I. Janoueix-Lerosey, O. Delattre, G. Schleiermacher, J. Vandesompele, F. Speleman, R. Noguera, M. Piqueras, J. Bénard, A. Valent, S. Avigad, I. Yaniv, R. G. Grundy,M. Ortmann, C. Shao, M. Schwab, R. Eils, T. Simon, J. Theissen, F. Berthold, F. Westermann, B. Brors, M. Fischer, Revised risk estimation and treatment stratification of low-and intermediaterisk neuroblastoma patients by integrating clinical and molecular prognostic markers. Clin. Cancer Res. 21, 1904-1915 (2015).
56. C. M. Johannessen, J. S. Boehm, S. Y. Kim, S. R. Thomas, L. Wardwell, L. A. Johnson, C. M. Emery, N. Stransky, A. P. Cogdill, J. Barretina, G. Caponigro, H. Hieronymus, R. R. Murray, K. Salehi-Ashtiani, D. E. Hill, M. Vidal, J. J. Zhao, X. Yang, O. Alkan, S. Kim, J. L. Harris, C. J. Wilson, V. E. Myer, P. M. Finan, D. E. Root, T. M. Roberts, T. Golub, K. T. Flaherty, R. Dummer, B. L.Weber, W. R. Sellers, R. Schlegel, J. A.Wargo, W. C. Hahn, L. A. Garraway, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
57. J. Park, Y. Hu, T. V. S. Murthy, F. Vannberg, B. Shen, A. Rolfs, J. E. Hutti, L. C. Cantley, J. LaBaer, E. Harlow, L. Brizuela, Building a human kinase gene repository: Bioinformatics, molecular cloning, and functional validation. Proc. Natl. Acad. Sci. U.S.A. 102, 8114-8119 (2005).
58. C. Y. Seiler, J. G. Park, A. Sharma, P. Hunter, P. Surapaneni, C. Sedillo, J. Field, R. Algar, A. Price, J. Steel, A. Throop, M. Fiacco, J. LaBaer. DNASU plasmid and PSI:Biology-Materials repositories: Resources to accelerate biological research. Nucleic Acids Res. 42, D1253-D1260 (2014).
59. D. J. Duffy, A. Krstic, T. Schwarzl, D. G. Higgins, W. Kolch, GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling. Mol. Cancer Ther. 13, 454-467 (2014).
60. A. Kiyatkin, E. Aksamitiene, Multistrip western blotting to increase quantitative data output. Methods Mol. Biol. 536, 149-161 (2009).
61. F. Hochgräfe, L. Zhang, S. A. O'Toole, B. C. Browne, M. Pinese, A. Porta Cubas, G. M. Lehrbach, D. R. Croucher, D. Rickwood, A. Boulghourjian, R. Shearer, R. Nair, A. Swarbrick, D. Faratian, P. Mullen, D. J. Harrison, A. V. Biankin, R. L. Sutherland, M. J. Raftery, R. J. Daly, Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res. 70, 9391-9401 (2010).
62. A. Oberthuer, D. Juraeva, L. Li, Y. Kahlert, F. Westermann, R. Eils, F. Berthold, L. Shi, R. D. Wolfinger, M. Fischer, B. Brors, Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J. 10, 258-266 (2010).
63. W. S. Hlavacek, J. R. Faeder, M. L. Blinov, R. G. Posner, M. Hucka, W. Fontana, Rules for modeling signal-transduction systems. Sci. STKE 2006, re6 (2006).
64. L. A. Chylek, B. Hu, M. L. Blinov, T. Emonet, J. R. Faeder, B. Goldstein, R. N. Gutenkunst, J. M. Haugh, T. Lipniacki, R. G. Posner, J. Yang, W. S. Hlavacek, Guidelines for visualizing and annotating rule-based models. Mol. Biosyst. 7, 2779-2795 (2011).
65. P. A. Iglesias, B. P. Ingalls, Control Theory and Systems Biology (MIT Press, Cambridge, 2010), 345 pp.
66. W. Kolch, Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6, 827-837 (2005).
67. M. Cirit, C.-C. Wang, J. M. Haugh, Systematic quantification of negative feedback mechanisms in the extracellular signal-regulated kinase (ERK) signaling network. J. Biol. Chem. 285, 36736-36744 (2010).
68. T. Nakakuki, M. R. Birtwistle, Y. Saeki, N. Yumoto, K. Ide, T. Nagashima, L. Brusch, B. A. Ogunnaike, M. Okada-Hatakeyama, B. N. Kholodenko, Ligand-specific c-Fos expression emerges from the spatiotemporal control of ErbB network dynamics. Cell 141, 884-896 (2010).
69. A. von Kriegsheim, D. Baiocchi, M. Birtwistle, D. Sumpton, W. Bienvenut, N. Morrice, K. Yamada, A. Lamond, G. Kalna, R. Orton, D. Gilbert, W. Kolch, Cell fate decisions are specified by the dynamic ERK interactome. Nat. Cell Biol. 11, 1458-1464 (2009).
70. C. P. Paweletz, L. Charboneau, V. E. Bichsel, N. L. Simone, T. Chen, J. W. Gillespie, M. R. Emmert-Buck, M. J. Roth, E. F. Petricoin III, L. A. Liotta, Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989 (2001).
71. J. E. Miller, The Chicago guide to writing about multivariate analysis (University of Chicago Press, Chicago, 2005), 487 pp.